Martin Eklund
Professor | Docent
E-mail: martin.eklund@ki.se
Telephone: +46852482501
Mobile phone: +46737121611
Visiting address: Nobels väg 12a, 17165 Solna
Postal address: C8 Medicinsk epidemiologi och biostatistik, C8 MEB Eklund, 171 77 Stockholm
About me
- I am professor of epidemiology at the Department of Medical Epidemiology and Biostatistics (MEB) at Karolinska Institutet (KI). I did all my undergraduate studies at Uppsala University, apart from a three-semester stint at the University of Otago in Dunedin, New Zealand, where I studied mathematics and biotechnology. I also did my PhD at Uppsala University, mainly focusing on computer intensive methods for statistical model choice and validation.
After finishing my PhD, I moved on to postdoc positions at the section for Global Safety Assessment at AstraZeneca and at the Department of Medical Epidemiology and Biostatistics, KI. During 2013 and 2014, I was based in San Francisco and worked at the Department of Surgery, University of California San Francisco (UCSF).
Since 2015, I am based at MEB where I focus my research on reducing the mortality of breast- and prostate cancer as well as the negative side effects of today’s imprecise diagnostics and treatment selection. To achieve this, I have together with a fantastic team of national and international colleagues, coworkers, and collaborators constructed research programs spanning across biomarker development, validation and implementation, prediction modeling and artificial intelligence, translational medicine, and clinical trials.
Research
- My research aims to reduce breast- and prostate cancer mortality through the use of individualized prevention, diagnostics, and treatment.
=== Prostate cancer ===
Stockholm3
The prostate-specific antigen (PSA) test is used to screen for prostate cancer but has a high false-positive rate that translates into unnecessary prostate biopsies and overdiagnosis of low-risk prostate cancers. STHLM3 (sthlm3.se) was a large-scale prospective and population-based prostate cancer diagnostic trial involving close to 60, 000 men in Stockholm 2013-2015 with the aim of to develop and validate a model to identify high-risk prostate cancer with better test characteristics. The two screening methods, PSA and the Stockholm3 test, were assessed and compared for safety and efficacy. The primary aim of the STHLM3 trial was to investigate if the Stockholm3 test could substantially reduce the proportion of men undergoing prostate biopsy whilst maintaining the sensitivity for detecting consequential prostate cancer (Gleason Score 7 or above) compared to PSA. The results showed that the Stockholm3 test could reduce the number of unnecessary prostate biopsies by close to 50% and decrease indolent cancers (Gleason 6, typically regarded as overdiagnosed cancers) by 20%, without reducing the sensitivity to detect consequential prostate cancer compared to using the PSA. The data from the trial provides a fantastic resource for studying prostate cancer diagnostics, and has since the publication of the main results in the Lancet Oncology 2015 been used in a large number of follow-up publications.
Stockholm3-MRI
We are currently conducting the STHLM3-MRI trials (NCT03377881). That MRI improves prostate cancer diagnostics has become clear over the last few years. During 2016 and 2017, we performed the “STHLM3 MRI Phase 1 – A paired diagnostic trial”, where we included 723 men referred for a prostate biopsy at six centra (4 in Stockholm and 2 in Norway). Stockholm-3 combined with MRI was shown to decrease both unnecessary biopsies and overdiagnosis by about 50% and at the same time increase the sensitivity for consequential prostate cancer (Gleason score ≥ 7) compared to using systematic biopsies on all men. The second stage of the STHLM3-MRI research program was conducted 2018-2020, where we assessed the combined use of risk prediction using the Stockholm3 test together with MRI and targeted biopsies in a large-scale (N=12, 750) prospective and population-based randomized screening-by-invitation setting. The aims of the trial was to shown improved specificity and reduced detection of clinically insignificant disease in early detection of prostate cancer without decreasing the sensitivity of clinically significant prostate cancers by combining the Stockholm-3 prediction model together with MRI and targeted prostate biopsies. The first papers from this trial were published in NEJM and the Lancet Oncology, respectively. In these manuscripts, we show that MRI with targeted and standard biopsy in MRI-positive men was noninferior to standard biopsy for detecting clinically significant prostate cancer, and markedly reduced detection of clinically insignificant cancer. The reduced rates of unnecessary biopsy and diagnosis of clinically insignificant cancer address key barriers impeding implementation of population-based screening for prostate cancer. We further demonstrated that the Stockholm3 prostate test can inform risk stratification before MRI and targeted biopsies in prostate cancer screening.
AI assisted prostate cancer pathology
Histopathological evaluation of prostate biopsies is critical to the clinical management of men suspected of having prostate cancer. Despite this importance, the histopathological diagnosis of prostate cancer is associated with a number of challenges: The large number of prostate biopsies being performed worldwide together with the shortage of well-trained uro-pathologists and the high inter- pathologist variability leads to suboptimal prostate cancer diagnostics and prognostication, with risks for under- and overtreatment. We have over the last years developed an artificial intelligence (AI) system to assist the pathologists in the evaluation of prostate biopsies, with the overarching aim of solving these problems. In articles published in the Lancet Oncology in 2020 and Nature Medicine 2022, we demonstrate that the system performs on par with internationally leading uro-pathologist for grading prostate needle biopsies. We are now working on further developing the AI system, in particular by:
1. Performing retrospective international multisite validation of the AI system to assess and improve the AI’s performance across different labs, technical platforms, and disease subtypes
2. Developing methods to go beyond today’s grading to improve prognostication
3. Linking the AI system with genomic profiling of tumor tissue to improve treatment selection
4. Performing prospective validation of the AI system in a randomized diagnostic histopathology trial (scheduled to start early 2024).
STHLM3-AS
Conservative management with active surveillance of men diagnosed with low-risk prostate cancer includes serial testing with PSA tests and systematic prostate biopsies for disease progression to offer selective delayed treatment with curative intent. A drawback with current active surveillance is the large number of prostate biopsies the men undergo, which leads to reduced adherence to follow-up biopsies with the risk of missing the curative window of progressing disease. In addition, biopsies increase the risk of severe infections. The objective of the prospective STHLM3-AS trial was to assess a less invasive and more cost-effective way to detect clinical significant prostate cancer in men on active surveillance including an improved blood-based Stockholm3 test for identification of men with increased risk of upgraded prostate cancer and use of MRI to select men for diagnostic workup with targeted prostate biopsies. The main results from the trial was published in JNCI in 2021.
ProBio
Approximately 30% of men diagnosed with prostate cancer develop lethal metastatic castration-resistant prostate cancer (mCRPC). Although recently approved new drugs are beneficial for many mCRPC patients they carry three serious disadvantages. First, these drugs are all very expensive. Second, the response rates to these drugs are low, ranging between 20-40%. This leads to suboptimal treatment and unnecessary side-effects. Third, there are no predictive treatment markers available in clinical care today, which leads to ineffective trial-and-error in treatment decisions. Our hypothesis is that treatment decisions based on molecular profiling will significantly increase progression free survival compared to current clinical care. The vast majority of CRPC metastasize to the bone, with low success rate in obtaining sufficient material. Therefore, we sequence circulating tumor DNA (ctDNA) consisting of DNA debris from apoptotic cancer being present at high levels in plasma. We are currently testing this hypothesis in the ProBio trial, a large, international, multicentre, randomized study in men with mCRPC that started in 2018. ProBio (NCT03903835) uses an outcome-adaptive randomization trial design, with the goal to learn as rapidly as possible which treatments are effective for which ctDNA biomarker profiles. We are currently working on extending the ProBio platform trial to also encompass men with metastatic hormone sensitive prostate cancer (mHSPC). The design and objectives of the ProBio trial have been described in a publication in Trials in 2020.
=== Breast cancer ===
The WISDOM trial
The WISDOM trial (wisdomstudy.org) investigates whether a risk-based approach to breast cancer screening is as safe and effective as annual mammograms. We will also determine whether women readily accept personalized screening and if knowledge of their own risks, and the reasons for less-frequent screening, will reduce anxiety about breast cancer. Finally, we will determine whether our personalized approach will lead to more of the highest-risk women deciding to use strategies that can prevent breast cancer. Participants in the personalized screening arm receive a risk assessment that includes family and medical history, breast density measurement, and genomic tests (SNPs and high-penetrance genes such as BRCA1/2). WISDOM is currently enrolling and will in total enroll 65, 000 women across sites covering the entire US. WISDOM is funded by the Patient Centered Research Outcomes Institute (PCORI) and NIH. We have described the design and objectives of WISDOM in a string of publications (see e.g. JNCI and JNCI Cancer Spectrum).
KARISMA
The KARISMA trial was a six-armed randomized, double-blinded, placebo controlled study that started in November 2016 and finished in 2020 to investigate the effectiveness of different doses of Tamoxifen to reduce mammography density, with the aim of improving breast cancer prevention. The purpose of KARISMA is to identify the lowest dose of Tamoxifen being within the equivalence limits of 20 mg Tamoxifen arm and to determine dose dependent adverse events and quality of life. Our hypothesis was that a lower dose of Tamoxifen has non-inferior ability to prevent breast cancer as a 20 mg dose, but results is markedly less side effects and is therefore more readily acceptable by women. The main results from the trial was published in JCO in 2021, and several follow-up manuscripts are currently being written.
=== Other diseases and conditions ===
COVID
The goal of the I-SPY COVID trial is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2, open label, randomised platform design, we aim to identify agents with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation. There are numerous potential effective therapies that warrant testing in clinical trials. Although several therapies are under investigation, each trial is a one-off effort, many are not randomized, and there is no coordinated rapid cycle learning. An adaptive platform trial is the ideal design, as it allows the rapid screening of many agents simultaneously. The study design features comparison of investigational agent efficacy using a Bayesian design against current standard of care (including remdesivir+dexamethasone as backbone therapy). The trial started in July 2020 and is accruing patients across 35 sites in the United States. The trial rationale is described in a recent publication in Nature Medicine.
Proximal hamstrings avulsions
PHACT is an international, prospective, multicentre, randomized controlled trial comparing operative to nonoperative treatment of proximal hamstrings avulsions. The aim of PHACT is to obtain reliable evidence for the effectiveness of the two basic treatment options (surgical versus non-surgical treatment) for patients with total proximal hamstrings avulsions. Our primary aim is to compare the patient reported functional outcome, as measured by the Perth hamstrings assessment tool (PHAT), of surgically treated hamstrings avulsions compared to non-operative treated ruptures. The primary outcomes of the study are the PHAT scores 24 months.
=== Group members ===
Nita Mulliqi (PhD student)
Hari Vigneswaran (PhD student)
Kelvin Szolnoky (PhD student)
Joel Andersson (PhD student)
Xiaoyi Ji (PhD student)
Chiara Micoli (PhD student)
Kimmo Kartasalo (postdoc)
Henrik Olsson (postdoc)
Alessio Crippa (senior research specialist)
Thorgerdur Palsdottir (postdoc)
Andrea Discacciati (statistician)
Vivekananda Lanka (database developer)
Geraldine Martinez Gonzalez (research assistant)
Previous group members
Matteo Titus (research assistant)
Álvaro Fernández Quílez (postdoc, now at Stavanger University Hospital, Norway)
Peter Ström (PhD student, graduated 2020. Now doing AI development in industry)
Anna Lantz (postdoc, now independent PI)
Andreas Karlsson (postdoc, now doing AI development in industry)
Weronika Wrzos-Kaminska (research assistant, now PhD student at EPFL, Switzerland)
=== Current research grants (as PI) ===
My research is supported by the Swedish Research Council (Vetenskapsrådet), the Swedish Research Council for Health, Working Life and Welfare (FORTE), the Swedish Cancer Society (Cancerfonden), Karolinska Institutet, the European Institute of Innovation & - Technology (EIT), Prostatacancerförbundet, Åke Wiberg Foundation, the Stockholm County Council (SLL), the Nordic Cancer Union (NCU), the Patient Centered Research Outcome Institutet (PCORI), and the National Institutet for Health (NIH).
Teaching
- I currently teach the course “Multivariable prediction modeling with applications in precision medicine” (LK2990) together with Mattias Rantalainen. In a collaboration Mieke Van Hemelrijck at King's College London, I am also responsible for the course "Clinical Cancer Epidemiology: From Prevention to Treatment and Patient Care".
Selected publications
- Article: NATURE MEDICINE. 2022;28(1):154-163
- Article: NEW ENGLAND JOURNAL OF MEDICINE. 2021;385(10):908-920
- Article: THE LANCET ONCOLOGY. 2021;22(9):1240-1249
- Article: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(17):1899-1908
- Article: JAMA ONCOLOGY. 2020;6(10):1581-1588
- Article: THE LANCET ONCOLOGY. 2020;21(2):222-232
- Article: JNCI CANCER SPECTRUM. 2018;2(4):pky067
- Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2017;109(5):djw290
- Review: NATURE REVIEWS CLINICAL ONCOLOGY. 2016;13(9):550-565
- Article: THE LANCET ONCOLOGY. 2015;16(16):1667-1676
Articles
- Journal article: NATURE REVIEWS UROLOGY. 2024;:1-4
- Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(32):3806-3816
- Article: NATURE MEDICINE. 2024;30(11):3291-3302
- Article: EUROPEAN UROLOGY ONCOLOGY. 2024;:S2588-9311(24)00229-3
- Journal article: ANNALS OF ONCOLOGY. 2024;35:s991-s992
- Journal article: ANNALS OF ONCOLOGY. 2024;35:s978
- Journal article: ANNALS OF ONCOLOGY. 2024;35:s980
- Article: NATURE MEDICINE. 2024;30(9):2623-2630
- Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2024;116(9):1459-1465
- Article: BMC UROLOGY. 2024;24(1):168
- Article: JOURNAL OF MAGNETIC RESONANCE IMAGING. 2024;60(2):458-468
- Journal article: THE LANCET ONCOLOGY. 2024;25(7):827-828
- Article: VIRCHOWS ARCHIV. 2024;484(6):995-1003
- Article: EUROPEAN UROLOGY ONCOLOGY. 2024;:S2588-9311(24)00133-0
- Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e1213
- Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e623
- Article: JAMA NETWORK OPEN. 2024;7(4):e247131
- Article: EUROPEAN UROLOGY ONCOLOGY. 2024;7(2):213-221
- Article: EUROPEAN UROLOGY OPEN SCIENCE. 2024;62:61-67
- Journal article: EUROPEAN UROLOGY. 2024;85:s1692-s1693
- Journal article: EUROPEAN UROLOGY. 2024;85:s1598
- Journal article: EUROPEAN UROLOGY. 2024;85:s1611
- Journal article: EUROPEAN UROLOGY. 2024;85:s1674-s1675
- Journal article: EUROPEAN UROLOGY. 2024;85:s348
- Journal article: EUROPEAN UROLOGY. 2024;85:s1402-s1403
- Journal article: EUROPEAN UROLOGY. 2024;85:s1534-s1535
- Article: JAMA NETWORK OPEN. 2024;7(2):e2354577
- Article: JOURNAL OF CLINICAL PATHOLOGY. 2023;77(1):22-26
- Article: NATURE GENETICS. 2023;55(12):2065-2074
- Article: JOURNAL OF HAND SURGERY GLOBAL ONLINE. 2023;5(6):733-739
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2023;57:s104-s105
- Article: BRITISH JOURNAL OF RADIOLOGY. 2023;96(1151):20230210
- Article: THE LANCET: DIGITAL HEALTH. 2023;5(10):e703-e711
- Article: JAMA NETWORK OPEN. 2023;6(9):e2332900
- Article: BRITISH JOURNAL OF CANCER. 2023;129(1):61-71
- Article: THE LANCET: DIGITAL HEALTH. 2023;5(7):e435-e445
- Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16_suppl):e18917
- Journal article: CRITICAL CARE EXPLORATIONS. 2023;5(6):e0930
- Article: HISTOPATHOLOGY. 2023;82(6):837-845
- Article: EUROPEAN UROLOGY OPEN SCIENCE. 2023;51:89-94
- Article: EUROPEAN UROLOGY FOCUS. 2023;9(3):455-462
- Article: JOURNAL OF MEDICAL IMAGING. 2023;10(Suppl 2):S22405
- Article: ECLINICALMEDICINE. 2023;58:101889
- Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e997
- Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e419
- Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e214
- Journal article: EUROPEAN UROLOGY. 2023;83:s1293-s1294
- Journal article: EUROPEAN UROLOGY. 2023;83:s1266-s1267
- Journal article: EUROPEAN UROLOGY. 2023;83:s1613-s1614
- Journal article: EUROPEAN UROLOGY. 2023;83:s1268
- Journal article: EUROPEAN UROLOGY. 2023;83:s379-s380
- Article: NATURE COMMUNICATIONS. 2022;13(1):7761
- Article: JAMA ONCOLOGY. 2022;9(1):88-94
- Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;44:46-51
- Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;44:69-75
- Article: JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY. 2022;19(9):1021-1030
- Article: ISCIENCE. 2022;25(7):104663
- Article: EUROPEAN UROLOGY. 2022;82(1):12-19
- Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;41:1-7
- Article: JAMA ONCOLOGY. 2022;8(7):1019-1026
- Article: VIRCHOWS ARCHIV. 2022;481(1):73-82
- Article: BIOINFORMATICS. 2022;38(13):3462-3469
- Article: BMJ OPEN. 2022;12(6):e060664
- Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2022;56(3):169-175
- Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e255
- Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e991
- Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e41
- Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;38:32-39
- Article: BJUI COMPASS. 2022;3(2):173-183
- Journal article: CANCER RESEARCH. 2022;82(4_Supplement):p5-19-04-p5-19-04
- Journal article: CANCER RESEARCH. 2022;82(4_Supplement):p5-19-01-p5-19-01
- Journal article: EUROPEAN UROLOGY. 2022;81:s915-s916
- Journal article: EUROPEAN UROLOGY. 2022;81:s913
- Journal article: EUROPEAN UROLOGY. 2022;81:s792-s793
- Journal article: EUROPEAN UROLOGY. 2022;81:s561-s562
- Journal article: EUROPEAN UROLOGY. 2022;81:s554-s555
- Article: BREAST CANCER RESEARCH AND TREATMENT. 2022;191(3):623-629
- Article: LAKARTIDNINGEN. 2022;119:21207
- Article: BIOINFORMATICS. 2021;37(21):3995-3997
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2021;33:s216-s217
- Journal article: INVESTIGATIVE UROLOGY. 2021;206(Supplement 3):e565-e566
- Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2021;55(4):299-306
- Article: PROSTATE CANCER AND PROSTATIC DISEASES. 2021;24(2):457-464
- Article: WORLD JOURNAL OF UROLOGY. 2021;39(6):1797-1804
- Article: VIRCHOWS ARCHIV. 2021;478(6):1109-1116
- Journal article: EUROPEAN UROLOGY. 2021;79:s1429
- Journal article: EUROPEAN UROLOGY. 2021;79:s1430
- Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2021;113(5):632-640
- Article: EUROPEAN UROLOGY FOCUS. 2021;7(3):546-553
- Article: CANCERS. 2021;13(7):1588
- Article: MODERN PATHOLOGY. 2021;34(3):660-671
- Article: PROSTATE CANCER AND PROSTATIC DISEASES. 2021;24(1):120-127
- Article: EUROPEAN UROLOGY OPEN SCIENCE. 2021;24:43-51
- Article: EUROPEAN UROLOGY OPEN SCIENCE. 2021;24:11-16
- Article: NATURE GENETICS. 2021;53(1):65-75
- Article: VIRCHOWS ARCHIV. 2020;477(6):777-786
- Article: RADIOLOGY. 2020;297(1):33-39
- Article: EUROPEAN UROLOGY ONCOLOGY. 2020;3(5):640-647
- Article: JOURNAL OF CLINICAL PATHOLOGY. 2020;73(10):630-635
- Article: THE LANCET: DIGITAL HEALTH. 2020;2(9):e468-e474
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2020;19:e519-e520
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2020;19:e260-e261
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2020;19:e182
- Article: BMC HEALTH SERVICES RESEARCH. 2020;20(1):448
- Journal article: INVESTIGATIVE UROLOGY. 2020;203:e1148
- Journal article: INVESTIGATIVE UROLOGY. 2020;203:e1100
- Article: JNCI CANCER SPECTRUM. 2020;4(2):pkaa016
- Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(6_suppl):tps378
- Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(6_suppl):tps379
- Article: RADIOLOGY. 2020;294(2):265-272
- Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2020;54(1):1-6
- Article: PLOS ONE. 2020;15(9):e0238217
- Article: JAMA NETWORK OPEN. 2019;2(11):e1914689
- Journal article: ANNALS OF ONCOLOGY. 2019;30:v354
- Journal article: ANNALS OF ONCOLOGY. 2019;30:v30-v31
- Article: EUROPEAN UROLOGY ONCOLOGY. 2019;2(5):490-496
- Article: JOURNAL OF HAND THERAPY. 2019;32(3):328-333
- Journal article: INVESTIGATIVE UROLOGY. 2019;201(Supplement 4)
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2019;18(1):e1532
- Article: INTERNATIONAL JOURNAL OF CANCER. 2019;144(5):1195-1204
- Article: PROSTATE CANCER AND PROSTATIC DISEASES. 2019;22(1):137-142
- Article: PLOS ONE. 2019;14(2):e0211918
- Article: EUROPEAN UROLOGY. 2018;74(6):722-728
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2018;17(14):e2898-e2899
- Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(11):1216-1221
- Article: EUROPEAN UROLOGY FOCUS. 2018;4(5):707-710
- Article: EUROPEAN UROLOGY. 2018;74(2):204-210
- Article: NATURE GENETICS. 2018;50(7):928-936
- Article: NATURE COMMUNICATIONS. 2018;9(1):2256
- Article: EUROPEAN UROLOGY FOCUS. 2018;4(3):385-387
- Article: PROSTATE CANCER AND PROSTATIC DISEASES. 2018;21(1):57-63
- Journal article: CANCER RESEARCH. 2018;78(4_Supplement):pd2-14-pd2-14
- Journal article: CANCER RESEARCH. 2018;78(4_Supplement):p4-12-03-p4-12-03
- Journal article: CANCER RESEARCH. 2018;78(4_Supplement):p3-09-02-p3-09-02
- Article: INTERNATIONAL JOURNAL OF CANCER. 2018;142(4):741-746
- Article: BREAST CANCER RESEARCH. 2018;20(1):14
- Article: BMC MEDICAL RESEARCH METHODOLOGY. 2018;18(1):3
- Article: PLOS ONE. 2018;13(7):e0200409
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2017;16(10):e2628-e2629
- Article: BMC UROLOGY. 2017;17(1):92
- Article: JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION : JAMIA. 2017;24(5):950-957
- Article: WORLD JOURNAL OF UROLOGY. 2017;35(6):895-896
- Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2016;108(12):djw165
- Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):5050
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2016;15(3):e97
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2016;15(3):e86
- Article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(3):251-258
- Article: ACTA ONCOLOGICA. 2016;55(1):45-51
- Article: PROSTATE. 2015;75(13):1467-1474
- Article: EUROPEAN UROLOGY. 2015;68(1):139-146
- Article: ANNALS OF MATHEMATICS AND ARTIFICIAL INTELLIGENCE. 2015;74(1-2):117-132
- Article: REGULATORY TOXICOLOGY AND PHARMACOLOGY. 2015;71(2):279-284
- Article: JOURNAL OF CHEMICAL INFORMATION AND MODELING. 2015;55(1):19-25
- Article: JOURNAL OF CHEMICAL INFORMATION AND MODELING. 2014;54(11):3211-3217
- Article: JOURNAL OF CHEMICAL INFORMATION AND MODELING. 2014;54(10):2647-2653
- Article: JOURNAL OF CHEMICAL INFORMATION AND MODELING. 2014;54(6):1596-1603
- Article: EUROPEAN UROLOGY. 2014;65(6):1184-1190
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2014;13(1):e339
- Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2014;13(1):e860
- Article: JOURNAL OF CHEMICAL INFORMATION AND MODELING. 2014;54(3):837-843
- Article: ANNALS OF INTERNAL MEDICINE. 2014;160(3):145
- Journal article: CHEMINFORM. 2013;44(31):no
- Article: JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN. 2013;27(3):203-219
- Article: BIOINFORMATICS. 2013;29(2):286-289
- Journal article: CURRENT TOPICS IN MEDICINAL CHEMISTRY. 2013;12(18):1980-1986
- Article: JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION. 2012;82(4):515-527
- Article: MOLECULAR INFORMATICS. 2012;31(2):173-179
- Article: JOURNAL OF CHEMICAL INFORMATION AND MODELING. 2011;51(8):1840-1847
- Article: EUROPEAN UROLOGY. 2011;60(1):21-28
- Article: BIOINFORMATICS. 2011;27(12):1719-1720
- Article: JOURNAL OF BIOMEDICAL SEMANTICS. 2011;240(Suppl 1):S6
- Article: PLOS ONE. 2010;5(12):e14353
- Article: JOURNAL OF CHEMINFORMATICS. 2010;2(1):5
- Article: MOLECULAR ECOLOGY. 2010;19(11):2229-2240
- Article: BMC BIOINFORMATICS. 2010;11:282
- Article: BMC BIOINFORMATICS. 2009;10:397
- Article: JOURNAL OF EVOLUTIONARY BIOLOGY. 2009;22(11):2267-2277
- Article: JOURNAL OF MICROBIOLOGICAL METHODS. 2008;75(2):219-224
- Article: BMC BIOINFORMATICS. 2008;9:360
- Article: BMC BIOINFORMATICS. 2008;9:181
- Article: BMC BIOINFORMATICS. 2007;8:59
- Article: FEMS MICROBIOLOGY ECOLOGY. 2006;57(1):26-39
- Show more
All other publications
- Book chapter: CANCER PREVENTION, DETECTION, AND INTERVENTION: LECTURE NOTES IN COMPUTER SCIENCE (INCLUDING SUBSERIES LECTURE NOTES IN ARTIFICIAL INTELLIGENCE AND LECTURE NOTES IN BIOINFORMATICS). 2025;p. 73-82
- Corrigendum: NATURE MEDICINE. 2024;30(11):3381
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(4_SUPPL):262
- Preprint: ARXIV. 2023
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16)
- Conference publication: EUROPEAN UROLOGY. 2023;83:S685-S686
- Conference publication: JOURNAL OF UROLOGY. 2023;209:E997-E998
- Conference publication: EUROPEAN UROLOGY. 2023;83:S379-S380
- Conference publication: JOURNAL OF UROLOGY. 2023;209:E214-E215
- Conference publication: JOURNAL OF UROLOGY. 2023;209:E419
- Editorial comment: EUROPEAN UROLOGY FOCUS. 2022;8(6):1617-1621
- Letter: JAMA ONCOLOGY. 2022;8(12):1852
- Corrigendum: EUROPEAN UROLOGY. 2022;82(1):e21
- Conference publication: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2022;205:a5284
- Review: EUROPEAN UROLOGY FOCUS. 2022;8(2):409-417
- Review: PROSTATE CANCER AND PROSTATIC DISEASES. 2022;25(2):165-173
- Conference publication: EUROPEAN UROLOGY. 2022;81:S913
- Conference publication: EUROPEAN UROLOGY. 2022;81:S915-S916
- Conference publication: EUROPEAN UROLOGY. 2022;81:S792-S793
- Conference publication: JOURNAL OF UROLOGY. 2022;207(5):E991-E992
- Letter: NATURE MEDICINE. 2022;28(1):9-11
- Editorial comment: JOURNAL OF UROLOGY. 2022;207(1):231
- Conference publication: EUROPEAN UROLOGY. 2022;81:S561-S562
- Conference publication: EUROPEAN UROLOGY. 2022;81:S554-S555
- Conference publication: JOURNAL OF UROLOGY. 2022;207(5):E41
- Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2021;385(22):2110-2111
- Editorial comment: BREAST CANCER RESEARCH AND TREATMENT. 2021;189(3):593-598
- Editorial comment: PATHOLOGY. 2021;53(5):565-567
- Review: EUROPEAN UROLOGY FOCUS. 2021;7(4):687-691
- Corrigendum: NATURE GENETICS. 2021;53(3):413
- Conference publication: CANCER RESEARCH. 2021;81(4)
- Conference publication: EUROPEAN UROLOGY. 2021;79:S1429
- Conference publication: EUROPEAN UROLOGY. 2021;79:S1430
- Preprint: SSRN ELECTRONIC JOURNAL. 2021
- Letter: BJU INTERNATIONAL. 2020;125(6):763-764
- Preprint: MEDRXIV. 2020;MEDRXIV
- Editorial comment: HISTOPATHOLOGY. 2020;76(6):790-792
- Preprint: ARXIV. 2020
- Conference publication: CANCER RESEARCH. 2020;80(4):ot3-03-02-ot3-03-02
- Preprint: SSRN ELECTRONIC JOURNAL. 2020
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(6)
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(6)
- Preprint: ARXIV. 2019
- Conference publication: CANCER RESEARCH. 2019;79(13):3361
- Conference publication: 2019;:3361
- Letter: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2019;111(7):748
- Letter: EUROPEAN UROLOGY. 2019;75(4):e104-e105
- Letter: HUMAN GENETICS. 2019;138(3):287-289
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(7):48
- Conference publication: CANCER RESEARCH. 2019;79(4):p4-09-03-p4-09-03
- Conference publication: CANCER RESEARCH. 2019;79(4):ot2-08-01-ot2-08-01
- Corrigendum: NATURE GENETICS. 2019;51(2):363
- Corrigendum: NATURE COMMUNICATIONS. 2019;10(1):382
- Letter: NPJ DIGITAL MEDICINE. 2019;2:101
- Conference publication: ANNALS OF ONCOLOGY. 2019;30:354
- Conference publication: ANNALS OF ONCOLOGY. 2019;30
- Editorial comment: EUROPEAN UROLOGY. 2018;74(6):739-740
- Letter: EUROPEAN UROLOGY. 2018;74(1):e10-e11
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(6):tps397
- Conference publication: JOURNAL OF GENERAL INTERNAL MEDICINE. 2018;33:S143-S144
- Conference publication: CANCER RESEARCH. 2018;78(4)
- Conference publication: CANCER RESEARCH. 2018;78(4)
- Editorial comment: EUROPEAN UROLOGY FOCUS. 2017;3(6):526-528
- Other: UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS. 2017;35(3):120
- Letter: NATURE REVIEWS CLINICAL ONCOLOGY. 2016;13(6):395-U82
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):e18281
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):tps1594
- Conference publication: CANCER RESEARCH. 2016;76:p6-02-08-p6-02-08
- Editorial comment: THE BMJ. 2016;352:i551
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(2):284
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(2):36
- Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2015;51:S167-S168
- Conference publication: CANCER RESEARCH. 2015;75(9_Supplement):p3-02-01-p3-02-01
- Letter: ANNALS OF INTERNAL MEDICINE. 2014;161(4):305
- Book chapter: PROGRESS IN PATTERN RECOGNITION, IMAGE ANALYSIS, COMPUTER VISION, AND APPLICATIONS: IFIP ADVANCES IN INFORMATION AND COMMUNICATION TECHNOLOGY. 2014;p. 231-240
- Editorial comment: NATURE REVIEWS CLINICAL ONCOLOGY. 2013;10(12):673-675
- Conference publication: CANCER RESEARCH. 2012;72:p3-02-12-p3-02-12
- Corrigendum: MOLECULAR INFORMATICS. 2012;31(10):752
- Review: CURRENT TOPICS IN MEDICINAL CHEMISTRY. 2012;12(18):1980-1986
- Meeting abstract: TOXICOLOGY LETTERS. 2012;211:S62
- Book chapter: ARTIFICIAL INTELLIGENCE APPLICATIONS AND INNOVATIONS: IFIP ADVANCES IN INFORMATION AND COMMUNICATION TECHNOLOGY. 2012;p. 166-175
- Book chapter: COMPUTATIONAL APPROACHES IN CHEMINFORMATICS AND BIOINFORMATICS. 2011;p. 57-92
- Show more
Grants
- Swedish Research Council1 January 2023 - 31 December 2025
- Swedish Research Council1 January 2023 - 31 December 2025
- Swedish Research Council1 January 2022 - 31 December 2025
- Swedish Research Council1 January 2021 - 31 December 2026
- Swedish Research Council1 January 2021 - 31 December 2024
- Swedish Research Council1 January 2020 - 31 December 2023
- Swedish Research Council1 January 2019 - 31 December 2022
- Improved active monitoring of patients with diagnosed low-risk prostate cancerSwedish Cancer Society1 January 2018
- Swedish Research Council1 January 2018 - 31 December 2020
- Swedish Research Council1 December 2017 - 31 December 2020
- Risk-based screening for prostate cancerSwedish Cancer Society1 January 2017
- Risk-based screening for prostate cancerSwedish Cancer Society1 January 2016
- Swedish Research Council for Health Working Life and Welfare1 January 2016 - 31 December 2018
- Risk-based screening for prostate cancerSwedish Cancer Society1 January 2015
- Swedish Research Council for Health Working Life and Welfare1 November 2012 - 31 October 2015
Employments
- Professor, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2022-
Degrees and Education
- Docent, Karolinska Institutet, 2013
- PhD Biostatistics, Uppsala University, 2010
- MSc Mathematics, Uppsala University, 2006
- MSc Molecular Biotechnology (civilingenjör), , Uppsala University, 2005
- BSc Macroeconomics, Uppsala University, 2004
Supervisor
- Kelvin Szolnoky, 2022